Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGLIPV)

Drug Name

GNF-5 Drug Info

Synonyms

GNF5; GNF 5

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting ABL messenger RNA (ABL mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
G-1128	DMHOMFK	Chronic myelogenous leukaemia	2A20.0	Discontinued in Phase 2	[2]
PP121	DMU8KTO	Discovery agent	N.A.	Investigative	[3]
PMID24900538C2c	DM5PATM	Discovery agent	N.A.	Investigative	[4]
PMID21561767C8h	DMABZH6	Discovery agent	N.A.	Investigative	[5]
PMID23441572C24	DMG4MLA	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan 28;463(7280):501-6.
2	Pharmaceutical Design And Development: A Molecular Biology Approach, T V Ramabhadran, 2005. Page(219).
3	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
4	Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
5	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
6	Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform. J Med Chem. 2013 Apr 11;56(7):3033-47.